Dec 9, 2015
Ph 2: Carfilzomib & lenalidomide-based treatment for newly diagnosed primary plasma cell leukemia
EMN12/HOVON129 Study Phase 2: To evaluate progression-free survival in adult pPCL patients by incorporation of carfilzomib and...
111
Dec 14, 2014
NCT02046070: Phase 2 to Evaluate the Oral Ixazomib (MLN9708) With Cyclophosphamide & Dex Myeloma
NCT02046070: Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients...
53
Dec 10, 2014
NCT02315716: Phase 2 -Carfilzomib/Cyclophosphamide/Dex With Maint. Carfilzomib - NDMM Cardamon Study
Cardamon Study KCd Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Multiple Myeloma (Cardamon) The Cardamon...
107
Dec 6, 2014
NCT02203643: Phase 2 - Carf/Cyclo./Dex Vs Carf/Len/Dex -> ASCT or 12 Cy Carf/Len/Dex - NDMM - FORTE
FORTE STUDY NCT02203643: Phase 2 - Carf/Cyclo./Dex Vs Carf/Len/Dex -> ASCT or 12 Cy Carf/Len/Dex - NDMM - FORTE KRd KCd ITALIAN STUDY...
253
Dec 14, 2013
NCT01980589: Phase 1b: Study of Carfilzomib, Cyclophosphamide and Dexamethasone in NDMM CHAMPION 2
CHAMPION 2 NCT01980589: Phase 1: A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly...
69
Dec 11, 2013
NCT01857115: Phase 1/2: EMN - Study of Wkly Carfilzomib, Cyclophosphamide and Dexamethasone In NDMM
wCCyd EMN European Myeloma Network NCT01857115: Phase 1/2: Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly...
112
Dec 11, 2013
NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in NDMM or L C Amyloid
NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic...
67
Dec 5, 2013
NCT01971658: Phase 3: Efficacy Study Comparing VTD Versus VCD as Induction NDMM - IFM2013-04
IFM2013-04 NCT01971658: Phase 3: Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone...
232
Dec 7, 2011
NCT01346787: EMN - Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone Newly Diagnosed Myeloma
EMN European Myeloma Network NCT01346787: Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma...
68
Dec 1, 2011
NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib
NCT01415882: Phase 2: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib...
61
Dec 16, 2010
NCT01093196: Phase 3: EMN01- Len/Dex Vs Melphalan/Pred/Len Vs Cyclophosamide/Pred/Len - elderly NDMM
EMN01 European Myeloma Network Newly Diagnosed Multiple Myeloma NCT01093196: Phase 3: Len and Dex Vs Melphalan Prednisone and Len Vs...
183
Dec 3, 2010
NCT01190787: Phase 2: EMN - Velcade/Melphalan/Pred or Velcade/Cycloposphamide/Pred or Velcade/Pred.
EMN - European Myeloma Network Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus...
159
Dec 16, 2009
Phase 2: Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed MM
Leukemia; 2009 Jul Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in...
89
Dec 4, 2009
NCT00833560: Phase 2: A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients NDMM
German DSMM Xia trial NCT00833560: Phase 2: A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated...
61
Dec 29, 2008
NCT00734877: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myel
Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ a randomized Phase III trial design to...
426
Dec 10, 2008
NCT00747877: Phase 3: HDM and second HSCT or Low dose Dex in Myeloma RRMM - Myeloma X Relapse
Myeloma X Relapse NCT00747877: Phase 3: HDM and second HSCT or Low dose Dex in Multiple Myeloma RRMM - Myeloma X Relapse Time Frame:...
50
Dec 3, 2008
NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With NDMM
NCT00609167: Phase 2: Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma...
65
Dec 21, 2007
NCT00507442: Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat NDMM EVOLUTION
EVOLUTION Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients (EVOLUTION)...
108
Dec 12, 2007
NCT00572169: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy.
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy. With this study - Total Therapy IIIB - researchers are...
351